Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Molecular characterization and distinguishing features of a novel human rhinovirus (HRV) C, HRVC-QCE, detected in children with fever, cough and wheeze during 2003

K.E. Ardena, b, C.E. Fauxa, b, N.T. O'Neilla, b, P. McErleana, b, A. Nitschec, S.B. Lamberta, b, M.D. Nissenad, b, e, T.P. Slootsa, b, d, e, I.M. Mackaya, b,∗

a Queensland Paediatric Infectious Diseases Laboratory, Sir Albert Sakzewski Virus Research Centre, Queensland Children’s Medical Research Institute, Royal Children’s Hospital, Queensland, Australia
b Clinical and Medical Virology Centre, University of Queensland, Queensland, Australia
c Robert Koch Institute, Centre for Biological Safety 1, Berlin, Germany
d Division of Microbiology, Queensland Health Pathology Service, Royal Brisbane Hospitals Campus, Queensland, Australia
e Department of Paediatrics and Child Health, Royal Children’s Hospitals, Queensland, Australia

A R T I C L E   I N F O

Article history:
Received 3 November 2009
Received in revised form 30 December 2009
Accepted 7 January 2010

Keywords:
Rhinovirus
Acute respiratory tract infection
HRV C
Wheeze
Respiratory virus epidemiology
Virus discovery

A B S T R A C T

Background: Human rhinoviruses (HRVs) are associated with more acute respiratory tract infections than any other viral group yet we know little about viral diversity, epidemiology or clinical outcome resulting from infection by strains, in particular the recently identified HRVs.

Objectives: To determine whether HRVC-QCE was a distinct HRV-C strain, by determining its genome and prevalence, by cataloguing genomic features for strain discrimination and by observing clinical features in positive patients.

Study design: Novel real-time RT-PCRs and retrospective chart reviews were used to investigate a well-defined population of 1247 specimen extracts to observe the prevalence and the clinical features of each HRV-QCE positive case from an in- and out-patient pediatric, hospital-based population during 2003. An objective illness severity score was determined for each HRVC-QCE positive patient.

Results: Differences in overall polyprotein and VP1 binding pocket residues and the predicted presence of a cis-acting replication element in 1B defined HRVC-QCE as a novel HRV-C strain. Twelve additional HRVC-QCE detections (1.0% prevalence) occurred among infants and toddlers (1–24 months) suffering mild to moderate illness, including fever and cough, who were often hospitalized. HRVC-QCE was frequently detected in the absence of another virus and was the only virus detected in three (23% of HRVC-QCE positives) children with asthma exacerbation and in two (15%) toddlers with febrile convulsion.

Conclusions: HRVC-QCE is a newly identified, genetically distinct HRV strain detected in hospitalized children with a range of clinical features. HRV strains should be independently considered to ensure we do not overestimate the HRVs in asymptomatic illness.

© 2010 Elsevier B.V. All rights reserved.

1. Background

Acute respiratory tract infections (ARTIs), a major cause of human morbidity and hospitalization, are most frequently viral in origin. The human rhinoviruses (HRVs) have for over a decade been associated, more than any other individual factor, with asthma1–3 and chronic obstructive pulmonary disease exacerbations4 and the majority of cold and flu-like illnesses (CFLIs).5,6 It has been shown that HRVs infect both upper and lower respiratory tract tissues.7,8 Classical serotypes (HRV-1 to 100) or “strains”, the term we use to indicate a molecular equivalent, form two accepted species within the heavily populated genus Enterovirus, family Picornaviridae. Despite the considerable economic burden of HRV infections,9 deliberate and comprehensive investigation of strain-specific clinical data is lacking.

In 2006 we proposed that a clade of divergent sequences belonged to a novel viral subgroup, HRV-A2,10 which we later redefined11 as a putative third species, HRV-C, in agreement with Lau et al.12 To date, nine complete polyprotein sequences of HRV-C strains have been determined from Australia (HRVC-QPM10), the United States (HRVC-NAT001/X-1, HRVC-NAT045/X-213 and

1386-6532/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
doi:10.1016/j.jcv.2010.01.001
HRVC-NY07414), Hong Kong (HRVC-C024, HRVC-C025 and HRVC-C02612) and Shanghai (HRVC-N4 and HRVC-N1015).

Many HRV strains have distinct genetic, antigenic, immunogenic and epidemiologic profiles which are similar in nature to those of other respiratory virus species including human respiratory syncytial virus (HRSV). The prospect of variation in sensitivity to antivirals is also an important reason to investigate each novel strain comprehensively, as is the chance that infection by specific HRV species could be associated with more severe illness or particular pre-existing conditions. Disappointingly, the possibility that discrete HRV strains exist as distinct viral entities is not accounted for in asymptomatic control populations because strain identification is not routinely conducted. As a consequence elevated prominence is, by default, assigned to HRVs as if to a single virus.

2. Objectives

We sought to genomically characterize HRV-QCE, an apparently distinct HRV-C strain whose novel subgenomic sequences were first detected in a child with exacerbated asthma and to define distinct molecular features among the HRV-Cs that are useful in discriminating strains for future studies and observe the clinical features amongst HRV-QCE positive patients.

3. Study design

Clinical specimens (n = 1247; three additions were made to the previously described HRV-QPM population10) were predominantly nasopharyngeal aspirates (NPA; 93%) from patients (59% male) aged 1 day to 80 years (mean 9.2 years, median 1.3 years) presenting to Queensland hospitals with symptoms of ARTI during 2003. Extracts were stored and tested as previously described.10 A clinical illness severity scoring system was applied as previously described.11 This study was approved by the Royal Children's Hospital and University of Queensland Medical Research Ethics Committees (specific approvals #2006/097 and #2008/020 and #2007000004).

Primers for genome deduction were first designed using early HRV-QCE sequences in 1A/1B (EU131891 and EU155152). All oligonucleotide sequences are available upon request. Additional primers supplemented the process.10,12,16 To confirm our primary sequence belonged to a distinct virus and was not the result of mixed HRV template, a second round of RT-PCR and sequencing of overlapping fragments was performed on RNA from the original patient specimen using newly designed HRV-QCE-specific primers. Discrepant sequence results were confirmed by additional rounds of RT-PCR and sequencing. Two specific diagnostic real-time RT-PCRs (RT-rtPCRs) were performed on the Rotor-GeneTM 3000 (Corbett Research) for diagnostic screening.

Polyprotease cleavage sites were sought using the NetPicoRNA server.17 Cre-acting replication element (cre) sequences18 were sought using the RNAalifold server and structures were predicted using MFold.19

4. Results

The polyprotein encoding sequence (GenBank #GQ323774) of HRV-QCE, a new member of the species Human rhinovirus C, spanned 6423 nt; shorter than all HEVs and HRVs except HRV-NY07414,2021. It had a G+C content of 43% and 2140 predicted amino acids terminating in an HRV-C-specific isoleucine.11 The HRVC-QCE polyprotein shared 54% average amino acid identity with HRV-A strains, 50% with HRV-Bs and 79% with other HRV-Cs. Ten protease cleavage sites were predicted to reduce the HRV-QCE polyprotein into typical picornavirus structural (VP1-4) and non-structural proteins (2A-C and 3A-D).17,22,23, HRV-QCE shared a translation initiation site (MGAQVS) with most other HRVs and three motifs crucial for RNA polymerase binding (YGDD, TFLKR and SIRWT) shared by HRVs, and HEVs24,25 but lacked two of three exposed VP1 motifs previously conserved among HRV polyproteins26 were absent in HRV-QCE. Phylogeny inferred from a discontinuous alignment of 10 amino acids in VP3 and VP1 which comprise the predicted intercellular adhesion molecule (ICAM)-1 footprint27 in major group HRV strains, placed HRVC-QCE amongst other HRV-Cs on a branch with HRV-1 (a minor group HRV which employs a different receptor) but distinct from the known major (employing the ICAM-1 molecule as receptor) or remaining minor group HRV strains (Fig. 1). Key residues on the VP1 BC loop involved in receptor contact with the VLDLR19 are missing in HRV-QCE and there are differences in the HI loop compared to the classical strains. Antigenic site A28 is absent in HRVC-QCE and the sequence at site B is unique to HRV-QCE. As with other HRV-C strains identified to date,4 the conserved loop sequence motif constituting a cre, R1NNINNA1A2R1NNNRR2 was identified (GCUAAGCAAAUCA) in 1B of HRV-QCE in the context of an appropriate predicted RNA stem-loop structure (not shown).

All classical HRV-A strains and 18/25 HRV-B strains are susceptible to the antiviral compound, pleconaril. Among the 25 key contact residues lining the antiviral binding pocket, there were 11 or 12 HRV-QCE-specific differences compared to HRV-A or HRV-B consensus sequences,29 respectively (Fig. 2); 11 differences exist between HRV-As and Bs and two differences between the consensus sequence of HRV-B sensitive versus resistant strains. Changes
Ref. 30. Representative HRV-A, -B and -C strains were included. The consensus amino acid sequence and a graphical representation of the contribution of residues occupying each position are shown above the alignment. Consensus residue numbering is from Ref. 30.

at two HRVC-QCE residues historically important for identifying naturally resistant strains were identified as Tyr152 (in resistant strains) to Phe152 and Val151 to Thr151. His325 conserved in nearly all other classical HRV strains, varied in HRVC-QCE and among other HRV-Cs. Other conserved HRV residues including Ile/Leu106 and Tyr/Phes/A150 differed in HRVC-QCE (Fig. 2).

To examine whether HRVC-QCE was a variant of a previously identified HRV strain, we first compared the full polyprotein against public sequence databases. The nearest matches were HRVC-C026 (93.5% identity, 2003 identical amino acids) and HRVC-QPM (92.9%, 1991 amino acids). The inferred amino acid sequences from complete 1D regions of eight HRVC-QCE-positive extracts (variants 1304320 = 60) of antigenically distinct and officially recognised HRV-A, -B, -C and representative HEV strains (those included in Palmenberg et al.; f-field strain). The HRVC-QCE (GenBank accession number GQ323774 and bankit numbers, 1304337, 1304336, 1304343, 1304341, 1304344, 1304335, 1304320) and HRVC-QPM strain variants are indicated with three-digit numbers.

No control patients were sampled in 2003. HRVC-QCE prevalence was bimodal with the major peak in summer when 3.5% of specimens were positive (7.6% of 119 specimens from February were positive representing 76.5% of all HRVC-QCE positives and 16.1% of all virus detections (n = 56) that month). HRVC-QCE was the only HRV detected in January. The remaining 23.1% of HRVC-QCE positive detections were detected in winter (0.8% of specimens, peaking at 3.8% of all viral detections in June). No other viruses were detected in 61.5% (n = 8) of HRVC-QCE positives (Table 1) leaving five extracts in which another viral sequence was identified. Respiratory picornaviruses were the most frequently detected virus at 40.9% of extracts. Isolation of HRVC-QCE in culture was not attempted because of the age of the clinical specimens.

Chart review of the 13 HRVC-QCE positive cases revealed presentation with lower respiratory tract illnesses (6/13; 46.2%), most commonly involving wheeze and administration of bronchodilators (Table 1). Antibiotics were not usually given to wheezers compared to non-wheezers. Eleven of the 13 cases (84.6%) were admitted to hospital and HRVC-QCE was the sole detection in 61.5% (n = 13) of 1247 specimen scores of 0 were obtained from an upper respiratory tract illness
HRVC-QCE as was Thr191, which is found in both resistant and of a previously described strain.11 The HRV literature notes infection as a novel strain nor above which it may best be called a variant identity thresholds below which a clinical detection may be defined consensus molecular criteria exist which define strains or provide

sensitive strains. The predicted HRV-C-specific sid region may affect receptor usage, antigenicity and sensitivity genome with truncations and sequence diversity in the 1D cap-

whom HRVC-QCE variants were detected. The relatively shortened the clinical features of a predominantly pediatric population from
dently genetically distinct HRV-C strain. We have summarised and distinguishing genetic features of a newly identified and evi-

5. Discussion

We have described the detection, polyprotein coding region and distinguishing genetic features of a newly identified and evident genetically distinct HRV-C strain. We have summarised the clinical features of a predominantly pediatric population from whom HRVC-QCE variants were detected. The relatively shortened genome with truncations and sequence diversity in the 1D capsid region may affect receptor usage, antigenicity and sensitivity to antivirals. Phe152 in VP1 is a distinctive feature of plecanaril resistant clinical HRV-B strains,30 and was present in the VP1 of HRVC-QCE as was Thr191, which is found in both resistant and sensitive strains. The predicted HRV-C-specific cre motif in 1B, the terminal isoleucine, the comparatively elevated G+C content and other features we have previously defined,11 identified HRVC-QCE as a candidate for the proposed new species HRV-C.

HRVC-QCE appears to be a distinct global pathogen however no consensus molecular criteria exist which define strains or provide identity thresholds below which a clinical detection may be defined as a novel strain nor above which it may best be called a variant of a previously described strain.11 The HRV literature notes infections which apparently have not elicited a cross-protective immune response as demonstrated by patients infected by distinct strains of the same or different species such over a defined period which share 62–93% amino acid identity in VP4.12,31,32 These biological data together with strain-determining genetic criteria permit the proposal of a practical molecular threshold, for example ≤93% amino acid identity, that could be used as a surrogate to define the biological distinctiveness of HRVs that cannot be cultured. Strain-defining criteria are especially useful to determine whether it is more accurate to consider “the HRVs” as a single group or as a collection of related but mostly antigenically discrete viruses, as is the norm for HRSV or HMPV for example. Applying strain-defining criteria to control populations may very likely redefine our concept of the

and a cystic fibrosis patient with an HRSV co-detection. There were no adult cases, despite adults comprising 15.8% of the screened population. Most (84.6%) patients were 2 years of age or younger.

Approximately half of HRV-C detections were from patients with lower respiratory tract symptoms and 85% of HRV-C detections were from hospitalized children. HRVC-QCE was the sole virus detected in over half of all cases.

The paucity of sequence data, strain-determining criteria and clinical investigations of the novel HRVs or of individual classical strains parallel our limited knowledge of the extent and clinical impact of HRV diversity. The most recent significant healthcare impact attributed to HRVs was the 2009 H1N1v influenza pandemic when HRVs were the most common viruses detected among patients qualifying, but laboratory-negative for, pandemic virus testing.13 Similar findings were described during the SARS-CoV outbreak.34

A lack of viral sequence data weakens our diagnostic and overall detection capabilities which limits our ability to define epidemiological features as well as the occurrence of strain-, or species-specific clinical outcomes and potentially differentiating genetic features. Due to the retrospective nature of our study, no temporally comparable control population was available for testing. This is a limitation among most other HRV studies as is the current inability to culture the newly identified HRVs. When a control population is included however, strain typing is usually not conducted and so a higher proportion of asymptomatic illness is attributed to all HRVs as a total group. Additionally, because we and others cannot fulfill Koch’s postulates for the currently unculturable HRV-Cs, the clinical observations cannot be specifically associated with the PCR-determined presence of HRVC-QCE RNA.

Our findings highlight the need to better understand the genomics, taxonomy, epidemiology and clinical impact of the newly identified HRV strains to accurately quantify the scope of their clinical impact as distinct respiratory viruses.

Competing interests

None.
Acknowledgments

We are grateful to Patrick Woo and Susanna Lau for primer and HRV strain sequences and to Daniel Gerlach for bioinformatics support. We thank Pathology Queensland Central for the provision of HRV strain sequences and to Daniel Gerlach for bioinformatics support. We thank Pathology Queensland Central for the provision of HRV strain sequences and to Daniel Gerlach for bioinformatics support. We thank Pathology Queensland Central for the provision of HRV strain sequences and to Daniel Gerlach for bioinformatics support.

Funding. This work was supported by an Australian NHMRC Project grant 455905.

References

1. Chauhan AJ, Inskip HM, Linaker CH, Smith S, Schreiber J, Johnston SL, et al. Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children. Lancet 2003;361(9373):1939–44.

2. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. Br Med J 1995;310:1225–9.

3. Rakes GP, Arruda E, Ingram JM, Hoover GE, Zambrano JC, Hayden FG, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. Am J Resp Crit Care Med 1999;159:785–90.

4. Johnston SL. Overview of virus-induced airway disease. Proc Am Thorac Soc 2005;2(2):150–6.

5. Rotbart HA, Hayden FG. Picornavirus infections: a primer for the practitioner. Arch Fam Med 2000;9:913–20.

6. Ruohola A, Waris M, Allander T, Ziegler T, Heikkinen T, Ruuskanen O. Viral etiology of common cold in children, Finland. Emerg Infect Dis 2009;15(2):344–6.

7. Arruda E, Boyle TR, Winther B, Pevear DG, Gwaltney Jr JM, Hayden FG. Localization of human rhinovirus replication in the upper respiratory tract by in situ hybridization. J Infect Dis 1995;171(5):1329–33.

8. Jakiela B, Brockman-Schneider R, Amineva S, Lee W-M, Gern JE. Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. Am J Respir Cell Mol Biol 2008;38(5):517–23.

9. Lambert SB, Allen KM, Carter RC, Nolan TM. The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children. Resp Res 2009;10(1):1–11.

10. McErlean P, Shackleton LA, Lambert SB, Nissen MD, Sloots TP, Mackay IM. Characterisation of a newly identified human rhinovirus, HRV-QPM, discovered in infants with bronchiolitis. J Clin Virol 2007;39(67–75.

11. McErlean P, Shackleton LA, Andrews E, Webster DR, Lambert SB, Nissen MD, et al. Distinguishing molecular features and clinical characteristics of a putative new rhinovirus species, human rhinovirus C (HRV C). PLoS One 2008;3(4):e1847.

12. Lau SKP, Yap CCY, Tsai H-W, Lee RA, So L-Y, Lau Y-L, et al. Clinical features and complete genome characterization of a distinct human rhinovirus genetic cluster, probably representing a previously undetected HRV species, HRV-C, associated with acute respiratory illness in children. J Clin Microbiol 2007;45(11):3655–64.

13. Kistler A, Avila PC, Rouskin S, Wang D, Ward T, Yagi S, et al. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronaviruses and human rhinovirus diversity. J Infect Dis 2007;196:817–25.

14. Palmenberg AC, Spiro D, Kuzmickas R, Wang S, Djikeng A, Rathe JA, et al. Sequencing and analyses of all known human rhinovirus genomes reveals structure and evolution. Science 2009;324(5923):55–9.

15. Huang T, Wang W, Bessaud M, Ren P, Sheng J, Yan H, et al. Evidence of recombination and genetic diversity in human rhinoviruses in children with acute respiratory infection. PLoS One 2009;4(7):e6355.

16. Simmons P, Welch J. Frequency and dynamics of recombination within different species of human enteroviruses. J Virol 2006;80(1):483–93.

17. Blom N, Hansen J, Blaas D, Brunak S. Cleave site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Prot Sci 1996;5:2203–16.

18. Cordey S, Gerlach D, Junier T, Zévédou BM, Kaiser L, Tapparelli C. The cis-acting replication elements define human enterovirus and rhinovirus species. RNA 2008;14(8):1568–78.

19. Verdaguer N, Fita I, Reithmayer M, Moser R, Blaas D. X-ray structure of a minor group human rhinovirus bound to a fragment of its cellular receptor protein. Nat Struct Mol Biol 2004;11(5):429–34.

20. Lukashev AN, Lashkevich VA, Ivanova OE, Koroleva GA, Hinkkanen AE, Ilonen J. Recombination in circulating human enterovirus B: independent evolution of structural and non-structural genome regions. J Gen Virol 2005;86:3281–90.

21. Oberste MS, Maher K, Schnurr D, Flemister MR, Lovchik JC, Peters H, et al. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol 2004;85:2577–84.

22. Skerr T, Sommergruber W, Blaas D, Gruenfelder P, Fraunfelder F, Pieler C, et al. Human rhinovirus 2: complete nucleotide sequence and proteolytic processing signals in the capsid protein region. Nucleic Acids Res 1985;13(6):2111–26.

23. Starnew G, Hughes PJ, Mountford RC, Minor PD, Almond JW. The complete nucleotide sequence of a common cold virus: human rhinovirus 14. Nucleic Acids Res 1984;12(20):7859–77.

24. Savolainen C, Laine P, Mulders MN, Hovi T. Sequence analysis of human rhinoviruses in the RNA-dependent RNA polymerase coding region reveals within-species variation. J Gen Virol 2004;85(8):2271–7.

25. Brown B, Oberste MS, Maher K, Pallansch MA. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J Virol 2003;77:8973–84.

26. Laine P, Blomqvist S, Savolainen C, Andries K, Hovi T. Alignment of capsid protein VP1 sequences of all human rhinovirus prototype strains: conserved motifs and functional domains. J Gen Virol 2006;87(1):129–38.

27. Blomqvist S, Savolainen-Kopra C, Paaanen A, Hovi T, Roivainen M. Molecular characterization of human rhinovirus field strains isolated during surveillance of enteroviruses. J Gen Virol 2009;90(6):1371–81.

28. Verdaguer N, Blaas D, Fita I. Structure of human rhinovirus serotype 2 (HRV2). J Mol Biol 2000;300:1179–94.

29. Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, et al. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol 2004;78(7):3653–74.

30. Ledford RM, Collins MS, Pevear DC. Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to plecanaril. Antiviral Res 2005;68(3):135–8.

31. Linsuwanon P, Paysangporn S, Samransamruajkit R, Theamboonlers A, Poovorawan Y. Recurrent rhinovirus infections in infants with refractory wheezing. Emerg Infect Dis 2009;15(6):978–80. Epub 2008 Mar 27.

32. Lau SK, Yap CC, Lin AW, Lee RA, So LY, Lau YL, et al. Clinical and molecular epidemiology of human rhinovirus C in children and adults in Hong Kong reveals a possible distinct human rhinovirus C subgroup. J Infect Dis 2009;200(7):1096–103.

33. Follin P, Lindqvist A, Nystrom K, Lindh M. A variety of respiratory viruses found in symptomatic travellers returning from countries with ongoing spread of the new influenza A/H1N1′′′′′′′′ virus strain. Euro Surveill 2009;14(24).

34. Schrag SJ, Brooks JT, Van BC, Parashar UD, Griffin PM, Anderson LJ, et al. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol 2004;85:2577–84.

35. Kistler A, Avila PC, Rouskin S, Wang D, Ward T, Yagi S, et al. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronaviruses and human rhinovirus diversity. J Infect Dis 2007;196:817–25.

36. Palmenberg AC, Spiro D, Kuzmickas R, Wang S, Dijkstra K, Rathe JA, et al. Sequencing and analyses of all known human rhinovirus genomes reveals structure and evolution. Science 2009;324(5923):55–9.

37. Huang T, Wang W, Bessaud M, Ren P, Sheng J, Yan H, et al. Evidence of recombination and genetic diversity in human rhinoviruses in children with acute respiratory infection. PLoS One 2009;4(7):e6355.

38. Simmonds P, Welch J. Frequency and dynamics of recombination within different species of human enteroviruses. J Virol 2006;80(1):483–93.